LATS1 and Alzheimer disease: Consistently, AD patient brains also exhibited increased binding of KIBRA to LATS1/2 and reduced binding of KIBRA to GLUA1, suggesting that LATS1/2 may sequester KIBRA from AMPAR complexes during AD pathogenesis, thereby contributing to synaptic dysfunction [16].